GT Biopharma appoints Charles Casamento to board; Alan Urban resigns

GT Biopharma, Inc.

Charles J. Casamento appointed to board effective May 1, 2023, to fill vacant seat.
Casamento to serve on Audit, Compensation, and Nominating & Governance committees.
Alan Urban resigned from board on May 1, 2023, to pursue new career opportunities.
Casamento has >35 years biopharma experience, formerly CEO of Questcor Pharmaceuticals and Osteologix.
Casamento currently serves on boards of four NASDAQ-listed biotechs: Eton, First Wave, PaxMedica, Relmada.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles J. Casamento

Director

GTBP · GT Biopharma, Inc.

Effective: 2023-05-01
Filed: May 4, 2023, 7:59 PM ET

the Registrant’s Board appointed Charles J. Casamento to fill a vacant seat on the Board

Departed

Alan Urban

Director

GTBP · GT Biopharma, Inc.

Effective: 2023-05-01
Successor: Charles J. Casamento
Filed: May 4, 2023, 7:59 PM ET

On May 1, 2023 Alan Urban resigned as a member of the Registrant’s Board of Directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Charles J. Casamento was appointed as Director at GT Biopharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Registrant’s Board appointed Charles J. Casamento to fill a vacant seat on the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Alan Urban resigned as Director at GT Biopharma, Inc..

Action: resigned
Role: Director

Exact text from the filing

On May 1, 2023 Alan Urban resigned as a member of the Registrant’s Board of Directors (the “Board”).

View on SEC.gov

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-015385

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.